Lyell Immunopharma (LYEL) Earnings Date, Estimates & Call Transcripts $0.39 -0.01 (-3.61%) As of 05/14/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Lyell Immunopharma Earnings Summary Lyell Immunopharma issued Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.18, which beat analysts' consensus estimates of -$0.19 by $0.01. Quarterly revenue was reported to be $0.01 million. With a trailing EPS of -$1.31, Lyell Immunopharma's earnings are expected to grow next year, from ($0.78) to ($0.70) per share. Latest Q1 Earnings DateMay. 13EstimatedConsensus EPS (May. 13) -$0.19 Actual EPS (May. 13) -$0.18 Beat By $0.01 Actual Revenue (May. 13) $0.01MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Lyell Immunopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataLYEL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LYEL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Lyell Immunopharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.17-$0.17-$0.17Q2 20251-$0.18-$0.18-$0.18Q3 20251-$0.18-$0.18-$0.18Q4 20251-$0.20-$0.20-$0.20 Lyell Immunopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025-$0.19-$0.18+$0.01-$0.18-$0.01M3/12/2025Q4 2024-$0.20-$0.72 -$0.52-$0.72-$0.01M11/7/2024Q3 2024-$0.20-$0.17+$0.03-$0.17-$0.03M8/7/2024--$0.20-$0.18+$0.02-$0.18-$0.01M5/6/2024Q1 2024-$0.20-$0.24 -$0.04-$0.24--2/28/2024Q4 2023-$0.21-$0.20+$0.01-$0.20$4.96M$0.01M11/7/2023Q3 2023-$0.27-$0.20+$0.07-$0.20$2.50M$0.03M8/8/2023Q2 2023-$0.30-$0.26+$0.04-$0.26$3.31M$0.03M Lyell Immunopharma Earnings - Frequently Asked Questions When did Lyell Immunopharma announce their last quarterly earnings? Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earning data on Tuesday, May 13, 2025. Learn more on LYEL's earnings history. Did Lyell Immunopharma beat their earnings estimates last quarter? In the previous quarter, Lyell Immunopharma (NASDAQ:LYEL) reported ($0.18) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.19) by $0.01. Learn more on analysts' earnings estimate vs. LYEL's actual earnings. How much revenue does Lyell Immunopharma generate each year? Lyell Immunopharma (NASDAQ:LYEL) has a recorded annual revenue of $61,000.00. How much profit does Lyell Immunopharma generate each year? Lyell Immunopharma (NASDAQ:LYEL) has a recorded net income of -$234.63 million. LYEL has generated -$1.31 earnings per share over the last four quarters. What is Lyell Immunopharma's EPS forecast for next year? Lyell Immunopharma's earnings are expected to grow from ($0.78) per share to ($0.70) per share in the next year. More Earnings Resources from MarketBeat Related Companies URGN Earnings Results TSHA Earnings Results MNMD Earnings Results RGNX Earnings Results CGEM Earnings Results AMLX Earnings Results UPB Earnings Results VERV Earnings Results MAZE Earnings Results ETON Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? This page (NASDAQ:LYEL) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
